Prescription drug · ANDA
Flucytosine NDC 40032-771
Flucytosine 250 mg/1 · Capsule · Oral · Novel Laboratories, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 40032-771-01 | 40032077101 | 100 CAPSULE in 1 BOTTLE (40032-771-01)Marketed from Jul 7, 2017 | |
| 40032-771-03 | 40032077103 | 30 CAPSULE in 1 BOTTLE (40032-771-03)Marketed from Jul 7, 2017 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Flucytosine
- Generic name (nonproprietary)
- flucytosine
- Active ingredients
- Flucytosine — 250 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Novel Laboratories, Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 204652
- Marketing start
- Listing expires
- Other FDA classes
- Nucleoside Analog (EXT)
- Identifiers
- Product ID 40032-771_6e35eb2f-b8be-422e-adcd-c11a2a6e3cb4SPL ID 6e35eb2f-b8be-422e-adcd-c11a2a6e3cb4SPL set ID ee98e0a9-c125-4b5c-ba4e-ca3c9a1f2b90RxCUI 197702, 197703UNII D83282DT06UPC 0340032771036
- Pharmacologic class
- Nucleoside Analog Antifungal
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N440032077101followed by a unit qualifier and the quantityPackage 40032-0771-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Flucytosine Capsules USP is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of r…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 204652
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Flucytosine | Flucytosine 500 mg/1 | CapsuleOral | Lupin Pharmaceuticals,Inc. | 43386-770 |
| Flucytosine | Flucytosine 250 mg/1 | CapsuleOral | Lupin Pharmaceuticals,Inc. | 43386-771 |
| Flucytosine | Flucytosine 250 mg/1 | CapsuleOral | AvPAK | 50268-331 |
| Flucytosine | Flucytosine 500 mg/1 | CapsuleOral | AvPAK | 50268-332 |
| Flucytosine | Flucytosine 250 mg/1 | CapsuleOral | Major Pharmaceuticals | 0904-6834 |
| Flucytosine | Flucytosine 500 mg/1 | CapsuleOral | Major Pharmaceuticals | 0904-6835 |
| Flucytosine | Flucytosine 500 mg/1 | CapsuleOral | Novel Laboratories, Inc. | 40032-770 |